Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma.
Deletion of serum lectin-reactive alpha-fetoprotein by acyclic retinoid: a potent biomarker in the chemoprevention of second primary hepatoma.
复制标题
无环类维生素A删除血清凝集素反应性甲胎蛋白：第二原发性肝癌化学预防中的有效生物标志物。
DOI：
--
复制
发表时间：
1997
影响因子：
11.5
通讯作者：
Yasutoshi Muto
中科院分区：
文献类型：
--
作者：
H. Moriwaki;Ichiro Yasuda;Y. Shiratori;T. Uematsu;M. Okuno;Yasutoshi Muto
癌症化学预防的一个目标是在潜在的癌前或恶性克隆扩展到临床可检测的肿瘤之前删除它们。然而，这种克隆性缺失尚未在临床研究中得到证实。我们已经评估了血清凝集素反应性甲胎蛋白（AFP-L3）的水平，这表明潜伏性肝癌细胞的存在，在一项随机对照试验中，使用无环类维生素A预防第二原发性肝癌的患者接受治疗，治愈初始肝癌。该试验涉及21名患者，每个无环类维生素A（每日600 mg）和安慰剂组，包括12个月的药物给药期和随后的随访期。血清AFP-L3测定在进入和在12个月的治疗期结束时，使用凝集素亲和电泳和抗体亲和印迹。尽管两种治疗均不影响血清总AFP水平，但在给药12个月后，无环类维生素A显著降低AFP-L3水平（P < 0.01）。无环类维生素A不仅能使入组时AFP-L3阳性患者的AFP-L3缺失，而且能阻止入组时AFP-L3阴性患者的AFP-L3出现（P < 0.01）。相比之下，安慰剂组在给药12个月后AFP-L3阳性患者的发生率显著高于入组时（P < 0.05）。治疗12个月后AFP-L3阳性的患者在随后的随访期内发生第二原发性肝癌的风险显著较高（P = 0.03）。无环类维生素A可能删除了一个克隆的潜伏性肝癌细胞产生AFP-L3，从而抑制第二原发性肝癌。血清AFP-L3可能是无环类维生素A化学预防第二原发性肝癌的一个有用的中间生物标志物。
A goal of cancer chemoprevention is the deletion of latent premalignant or malignant clones before they expand to a clinically detectable tumor. However, such clonal deletion has not been demonstrated in clinical studies. We have evaluated serum levels of lectin-reactive alpha-fetoprotein (AFP-L3), which suggests the presence of latent hepatoma cells, in a randomized controlled trial that used acyclic retinoid to prevent second primary hepatomas in patients who had received treatments that cured initial hepatomas. The trial involved 21 patients in each acyclic retinoid (600 mg daily) and placebo group and consisted of a 12-month period of drug administration and a subsequent follow-up period. Serum AFP-L3 was determined at entry and at the end of the 12-month treatment period using lectin-affinity electrophoresis and antibody-affinity blotting. Although neither treatment affected serum levels of total AFP, acyclic retinoid significantly reduced AFP-L3 levels after a 12-month administration (P < 0.01). Acyclic retinoid not only deleted AFP-L3 from patients who had been positive for AFP-L3 at entry but also prevented the appearance of AFP-L3 in patients who had been negative at entry (P < 0.01). In contrast, placebo significantly raised the incidence of AFP-L3-positive patients after a 12-month administration from that at entry (P < 0.05). Patients positive for AFP-L3 after a 12-month treatment had a significantly higher risk of second primary hepatomas in the subsequent follow-up period (P = 0.03). Acyclic retinoid may have deleted a clone of latent hepatoma cells producing AFP-L3 and thereby inhibited second primary hepatomas. Serum AFP-L3 may be a useful intermediate biomarker in the chemoprevention of second primary hepatomas by acyclic retinoid.
类维生素A化学预防呼吸消化道癌症：从基础研究到临床。
DOI：
--
发表时间：
1995
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research.
影响因子：
--
作者：
KiHong,W;Lippman,SM;Hittelman,WN;Lotan,R
通讯作者：
Lotan,R
影响因子：
2
作者：
ROBINS, J
通讯作者：
ROBINS, J
影响因子：
158.5
作者：
HONG, WK;LIPPMAN, SM;GOEPFERT, H
通讯作者：
GOEPFERT, H